User Reviews for Mozobil

The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.

Filter by:

Learn more about Mozobil.

Condition	Reviews	Compare	Avg. Ratings
Multiple Myeloma	0 reviews	46 medications	Not rated - Be the first
Non-Hodgkin's Lymphoma	0 reviews	26 medications	Not rated - Be the first

Reviews for Mozobil

There are no reviews - Be the first

Related Mozobil Information

Availability Prescription only

CSA Schedule Not a controlled drug

Pregnancy Category Positive evidence of risk

Approval History Drug history at FDA

FDA Consumer Updates

More FDA Updates...

Related Pages

Drug Class

Hematopoietic stem cell mobilizer
Other immunostimulants

Recently Approved

Mitosol
Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.
Sklice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ...
Jentadueto
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ...
Kalydeco
Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated ...
Erivedge
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ...

More...

Get Updates by Email

Email me about Mozobil:

Related News and Articles

Cell Therapeutics Withdraws New Drug Application for Pixuvri and Plans to Resubmit in 2012 30 January 2012
Cell Therapeutics, Inc. ("CTI") announced today that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone) for the...
FDA Approves Subcutaneous Administration of Velcade In All Approved Indications 24 January 2012
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced...
FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 3 January 2012
Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee...
Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting 16 December 2011
ZOLINZA in Combination with Bortezomib Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed and/or Refractory Multiple...
Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy 15 December 2011
Dec 15, 2011 - Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against...

Help and Support

Looking for answers? Ask a question or go join the Mozobil support group to connect with others who have similar interests.

Did you find this page helpful? Yes No

Support

About Drugs.com

Your Privacy

Follow us on: Google+ Facebook Twitter

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.

Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.

We comply with the HONcode standard for trustworthy health information.
Verify here

Terms of Use · Privacy Policy

Browse all medications A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Advanced Phonetic
Search:

User Reviews for Mozobil

Reviews for Mozobil

See also...

Related Mozobil Information